Search | Clinical Trials Finder

Conditions: Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
Interventions: RM-131, Placebo; Drug
Lead sponsor: Motus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 30
States / cities: Dothan, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 27 more

Conditions: Neuropathic Pain
Interventions: BMS-741672, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Tustin, California • Palm Beach Gardens, Florida • St. Petersburg, Florida + 5 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, PF-04603629; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Phoenix, Arizona • San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: muraglitazar; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 108
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 105 more

Conditions: Diabetic Macular Edema
Interventions: MYL-1701P, Eylea; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 13
States / cities: Phoenix, Arizona • Sacramento, California • St. Petersburg, Florida + 9 more

Conditions: Chronic Kidney Disease
Interventions: AZD5718, Dapagliflozin 10 mg, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 22
States / cities: Canoga Park, California • La Mesa, California • San Carlos, California + 19 more

Conditions: Diabetic Peripheral Neuropathy
Interventions: Mazisotine, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 34
States / cities: Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more

Conditions: Type 1 Diabetes
Interventions: Victoza, Placebo, Dapagliflozin 10mg Tab; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Diabetic Retinopathy
Interventions: Tarcocimab, Sham injection; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 38
States / cities: Tucson, Arizona • Fullerton, California • Glendale, California + 34 more

Conditions: Diabetic Peripheral Neuropathic Pain, Diabetic Peripheral Neuropathy
Interventions: ETX-018810, Placebo; Drug
Lead sponsor: Eliem Therapeutics (UK) Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 22
States / cities: Mobile, Alabama • Phoenix, Arizona • Fresno, California + 17 more

Conditions: Venous Leg Ulcer, Venous Leg, Diabetic Foot, Diabetic Foot Ulcer, Foot Ulcer, Diabetic, Ulcer Foot, Leg Ulcer, Ulcer Venous, Ulcer
Interventions: ACApatch™, caregraFT™, Standard of Care; Other
Lead sponsor: Tiger Biosciences, LLC.; Industry
Eligibility: 21 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Monroeville, Pennsylvania

Conditions: Painful Diabetic Peripheral Neuropathy
Interventions: ricolinostat, Placebo; Drug
Lead sponsor: Regenacy Pharmaceuticals LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 35
States / cities: Anniston, Alabama • Phoenix, Arizona • Huntington Beach, California + 30 more

Conditions: Diabetic Nephropathy
Interventions: Pyridoxamine Dihydrochloride, Placebo; Drug
Lead sponsor: NephroGenex, Inc.; Industry
Eligibility: 25 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Impaired Wound Healing, Venous Insufficiency of Leg, Diabetic Ulcers
Interventions: Harvesting Device (CelluTome©); Device
Lead sponsor: SerenaGroup, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 18
States / cities: Boca Raton, Florida • Homestead, Florida • Largo, Florida + 15 more

Conditions: Diabetic Foot Ulcers
Interventions: DSC127, placebo vehicle gel, Standard of Care gel, Aquasite; Drug
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 33
States / cities: Mesa, Arizona • Phoenix, Arizona • Castro Valley, California + 25 more

Conditions: Type 2 Diabetes
Interventions: Colesevelam hydrochloride; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 46
States / cities: Jonesboro, Arkansas • Beverly Hills, California • Carmichael, California + 43 more

Conditions: Diabetic Foot Ulcer
Interventions: Standard of Care, PuraPly AM, PuraPly XT; Other · Device
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Clevland, Ohio

Conditions: Diabetes Mellitus Type 2
Interventions: Placebo, RO6807952; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Chula Vista, California • Cincinnati, Ohio

Conditions: Diabetic Foot, DFU, Diabetic Foot Ulcer, Foot Ulcer, Diabetic, Ulcer Foot, Venous Leg Ulcer, Leg Ulcer, Leg Ulcers Venous, Ulcer
Interventions: Standard of Care DFU, Tri-Membrane Wrap™ DFU, Membrane Wrap™ DFU, Membrane Wrap-Lite™ DFU, Membrane Wrap-Hydro™ DFU, Standard of Care VLU, Tri-Membrane Wrap™ VLU, Membrane Wrap™ VLU, Membrane Wrap-Lite™ VLU, Membrane Wrap-Hydro™ VLU; Other
Lead sponsor: BioLab Holdings; Industry
Eligibility: 18 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philidelphia, Pennsylvania

Conditions: Impaired Glucose Tolerance, Obesity, Diabetes
Interventions: Physical Activity Counseling; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 60 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes, Hypoglycemia
Interventions: BHT-3021, BHT-Placebo; Drug
Lead sponsor: Bayhill Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 10
States / cities: Birmingham, Alabama • Fresno, California • Aurora, Colorado + 7 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, MSDC-0602 100 mg, MSDC-0602 250 mg, Pioglitazone; Drug
Lead sponsor: Metabolic Solutions Development Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 14
States / cities: Goodyear, Arizona • Chula Vista, California • Los Angeles, California + 11 more

Conditions: Diabetic Foot Ulcers (DFUs)
Interventions: E-GRAFT ™, FIBRACOL™; Other · Device
Lead sponsor: Skye Biologics Holdings, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Choroidal Neovascularization, Diabetic Retinopathy, Diabetic Macular Edema
Interventions: PF-04523655 (Stratum I), ranibizumab, PF-04523655 (Stratum II); Drug
Lead sponsor: Quark Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 20
States / cities: Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 17 more

Search by objective public record fields.

Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis

BMS-741672 for Diabetic Neuropathic Pain

Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects

Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain

Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.

Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy

Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes

Clinical Trial to Evaluate Blister Graft Utilizing a Novel Harvesting Device for Treatment of Venous Leg Ulcers

Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers

WelChol® With Metformin in Treating Patients With Type 2 Diabetes

A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers

A Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers

Enhancing Fitness in Older Pre-diabetic Veterans

Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus

A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients

Clinical Trial Evaluating an Amnion Membrane Allograft for Use in the Management of Non- Healing Diabetic Foot Ulcers Versus Standard Of Care

PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)